Baseline characteristics of patients with COPD (chronic bronchitis, emphysema) who require LABA and LAMA (both free and fixed combination) for maintenance therapy other than tiotropium+olodaterol fixed dose combination (Tio+Olo FDC) assessed in parallel with the PMS of Tio+Olo FDC Respimat, BI trial number 1237.34
- Conditions
- COPD(chronic bronchitis, emphysema)
- Registration Number
- JPRN-UMIN000023629
- Lead Sponsor
- ippon Boehringer Ingelheim Co.,LTD
- Brief Summary
Mild COPD was slightly higher in the BCS than in the PMS. The mean post dose percent FEV1 and FEV1 FVC were numerically slightly higher in the BCS than in the PMS. The proportion of comorbidities, benign prostatic hyperplasi and gastroesophageal reflux disease, was numerically higher and lower, respectively, in the BCS than in the PMS. The proportion of previously received respiratory medication was higher in the BCS than in the PMS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 474
Not provided
Patients who are prescribed Tio+Olo FDC, Patients who have already been registered in this study once (re-entry of patients is not allowed). Patients who are participating in a clinical trial or registry. Patients who have a contraindication to Tio+Olo FDC defined in the package insert for Tio+Olo FDC.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method